Wickramasinghe Dineli
Oncology Research, Amgen Inc., South San Francisco, California 94080, USA.
Discov Med. 2013 Oct;16(88):149-52.
Cancer immunotherapy attempts to exploit the capability of the immune system to attack malignant cells. Recent results suggest that clinical responses in patients point to this new mechanism as potentially beneficial in harnessing the immune system for combating established malignancies. These checkpoint-related immunotherapies rely on engaging a subset of T cells in anti-tumor immune responses. BiTE® (Bi-specific T cell engager) represents a distinct modality that directly engages any T cell and a specific antigen expressing tumor cell. The approach offers the advantage of engaging T cells and patient tumor cells that differentially express a specific cell surface antigen. The specificity confers redirected tumor cell killing and recent clinical data with the BiTE blinatumomab show evidence of clinical remissions. The characteristics of a suitable BiTE with the benefit of CD3 mediated T cell recognition and articulation of tumor specific antigens combined in this therapeutic modality is described here.
癌症免疫疗法试图利用免疫系统攻击恶性细胞的能力。最近的结果表明，患者的临床反应表明这种新机制在利用免疫系统对抗已形成的恶性肿瘤方面可能有益。这些与检查点相关的免疫疗法依赖于在抗肿瘤免疫反应中激活一部分T细胞。双特异性T细胞衔接器（BiTE®）代表了一种独特的模式，它直接激活任何T细胞和表达特定抗原的肿瘤细胞。这种方法的优点是能够激活差异表达特定细胞表面抗原的T细胞和患者肿瘤细胞。这种特异性赋予了重定向肿瘤细胞杀伤能力，最近关于双特异性抗体blinatumomab的临床数据显示了临床缓解的证据。本文描述了一种合适的BiTE的特征，该BiTE具有CD3介导的T细胞识别优势，并在此治疗模式中结合了肿瘤特异性抗原的表达。
